8-K: Quantum-Si Reports Q3 2024 Results, Sales Pipeline Accelerates Despite Lengthening Sales Cycle

Quantum-Si announced its third quarter 2024 financial results, highlighting revenue of $787,000 and an accelerating sales pipeline, while also noting a lengthening sales cycle impacting full-year revenue guidance.

Summary

• Quantum-Si reported a revenue of $787,000 for the third quarter of 2024, with a gross profit of $367,000 and a gross margin of 47%.
• For the nine months ended September 30, 2024, the company's revenue was $1.9 million, with a gross profit of $990,000 and a gross margin of 53%.
• Total operating expenses for the third quarter were $28.5 million, while adjusted operating expenses were $26.0 million.
• The company experienced a net loss of $25.3 million in the third quarter and an adjusted EBITDA of negative $24.5 million.
• As of September 30, 2024, Quantum-Si had $196.3 million in cash, cash equivalents, and marketable securities.
• The company has updated its full-year 2024 guidance for adjusted operating expenses to approximately $100 million and total cash usage to approximately $92 million.
• Quantum-Si expects its current cash balance to provide a runway into the second half of 2026.
• The company is on track to launch two new kits by the end of the year.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects such as an accelerating sales pipeline and new product launches, the company is facing challenges with a lengthening sales cycle and is unlikely to meet its full-year revenue guidance. The company is also still operating at a loss.

Positives

• The sales pipeline is accelerating, indicating growing market interest in Quantum-Si's products.
• The company is on track to launch two new kits by the end of the year, which is expected to drive further market adoption.
• Quantum-Si has successfully reduced adjusted operating expenses year-to-date while funding commercialization efforts.
• The company has a strong cash position of $196.3 million, providing a runway into the second half of 2026.
• The company has made key executive appointments to strengthen its leadership team.
• The integration of Platinum Next-Generation Sequencing by Liberate Bio demonstrates the technology's value and potential.
• The company is seeing adoption of its products across multiple market segments, including academic research, pharma/biotech, and contract research organizations.

Negatives

• The company is experiencing a lengthening sales cycle, which is impacting its ability to achieve its full-year revenue guidance.
• The company's net loss for Q3 2024 was $25.3 million, and adjusted EBITDA was negative $24.5 million.
• The company's revenue of $787,000 for Q3 2024 is below the guided revenue range.
• The company's gross margin is expected to be variable in the near term due to the initial stages of commercialization and product mix.

Risks

• The company may not achieve its full-year revenue guidance due to a lengthening sales cycle.
• The company's gross margin is expected to be variable in the near term.
• The company is still in the early stages of commercialization, which presents inherent risks.
• The company is experiencing ongoing leadership transitions.
• The company may face challenges in raising financing in the future.
• The company faces competition from other companies in the proteomic analysis market.

Future Outlook

The company expects its current cash balance to provide a runway into the second half of 2026 and anticipates continued quarter-over-quarter growth. They are also on track to launch two new kits by the end of the year and are looking forward to revealing more details on their technology roadmap at their upcoming Investor Day.

Management Comments

• Jeff Hawkins, President and CEO, stated that there has been clear improvement in commercial execution and the overall acceleration of the sales pipeline under the leadership of the new CCO.
• Hawkins also noted that the company has observed some lengthening of the sales cycle in the third quarter, making it unlikely that they will achieve their full-year guided revenue range.
• Hawkins expressed confidence in the long-term commercial opportunity for Platinum and the growth of the proteomics market.
• Hawkins stated that the company is on track to deliver two new kits by the end of the year.

Industry Context

The announcement reflects the challenges faced by companies in the tools space, with a lengthening sales cycle impacting revenue. However, Quantum-Si's focus on proteomics and its innovative Platinum technology positions it well for long-term growth in this expanding market. The company's progress in commercialization and product development is also noteworthy in the context of the broader industry.

Comparison to Industry Standards

• Quantum-Si's revenue of $787,000 for the quarter is relatively low compared to established life science tools companies, such as Illumina or Thermo Fisher Scientific, which report revenues in the hundreds of millions or billions per quarter.
• The company's gross margin of 47% is within the range of other early-stage biotech companies, but lower than the gross margins of more mature companies in the sector.
• The adjusted EBITDA of negative $24.5 million indicates that the company is still in a growth phase and is not yet profitable, which is typical for companies in this stage of development.
• The company's cash runway into the second half of 2026 is a positive sign, as it provides the company with sufficient time to execute its commercialization strategy.
• The company's focus on proteomics is aligned with the growing trend in the life sciences industry, as proteomics is increasingly recognized as a key area for drug discovery and diagnostics.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the company's inability to meet its full-year revenue guidance.
• Employees may be impacted by the ongoing leadership transitions.
• Customers may benefit from the new product launches and the company's focus on innovation.
• Suppliers may see increased demand as the company's sales pipeline accelerates.
• Creditors may be reassured by the company's strong cash position and runway into the second half of 2026.

Next Steps

• The company will launch two new kits by the end of the year.
• The company will host an Investor Day on November 20, 2024.
• The company will continue to focus on commercializing its Platinum instrument and expanding its market reach.

Key Dates

Keywords

proteomics, protein sequencing, Platinum, next-generation sequencing, financial results, revenue, EBITDA, operating expenses, commercialization, sales pipeline